by Mayur Kumar | Jun 14, 2022 | Blog
Pharmaceutical representatives can now wait in the comfort of their own home, have a soothing cup of tea in their hands and be ready for an eloquent discussion on disease pathology, drug mechanisms and patient management issues with the doctor. As ideal as this...
by Mayur Kumar | Jun 13, 2022 | Blog
Since the Orphan Drug Act was passed in 1983, the number of rare disease drug approvals in the US has significantly risen. Between 1983 and 2020, a total of 5,131 drugs and biologics received orphan drug designation. One-third of the industry’s R&D pipeline is now...
by Mayur Kumar | Jun 13, 2022 | Blog
With shrinking pipelines, increasing treatment costs, stiffer competition, and stricter regulations, pharma companies struggle more than ever to make their drugs succeed. With orphan drugs (ODs), commercialization is even more difficult given the lack of knowledge...
by Mayur Kumar | Jun 13, 2022 | Blog
A handful of factors have fueled the importance of multichannel marketing (MCM) in the pharmaceutical industry: a steady decline in physician access (only 55% of prescribers included in the most recent ZS AccessMonitor report were considered readily accessible to...
by Mayur Kumar | Jun 13, 2022 | Blog
In the beginning, digital was kind of a nice-to-have idea added to pharma marketing promotion. Then it became indispensable but still part of other offline activities (for too long medical reps’ visits were the only channel to approach a doctor). But next came the...
